Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | POLA1 | P09884 | 1/20 | 0.76 |
| ▸ | POLD1 | P28340 | 1/20 | 0.76 |
| ▸ | TK1 | P04183 | 5/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALB | P02768 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | DTYMK | P23919 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23405862 | 0.90 | POLB (0.76) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL15948322 | 0.90 | POLB (0.76) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL18923744 | 0.90 | POLB (0.76) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL24058347 | 0.90 | POLB (0.76) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL17225234 | 0.90 | POLB (0.76) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL21555526 | 0.89 | POLB (0.69) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL23635762 | 0.89 | POLB (0.69) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL23106227 | 0.88 | POLB (0.70) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL21308086 | 0.88 | POLB (0.70) | POLBPOLA1POLD1TK1P2RY2 | |
| SCHEMBL24370822 | 0.88 | POLB (0.72) | POLBPOLA1POLD1TK1DTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670161-B1 | Full-length human DNA polymerase-alpha catalytic polypeptide subunit having a specific amino acid sequence; has polymerase activity and wherein said composition lacks primase activity. | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY | 2003-12-30 | — | — | US | disclosed |
| US-20010039263-A1 | Chimeric oligonucleotides and the use thereof | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN | 2001-11-08 | — | — | US | disclosed |
| US-6100023-A | INTERACTING CATALYTIC POLYPEPTIDE, NON-HUMAN NUCLEIC ACID POLYMERASES AND A DRUG WHICH POTENTIALLY DEACTIVATES POLYMERASE AND EVALUATING DEACTIVATION OF POLYMERASES; SCREENING CHEMOTHERAPEUTICS FOR MUTAGENICITY/CARCINOGENICITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY (US) | 2000-08-08 | — | — | US | disclosed |
| US-6008045-A | A PURIFIED NUCLEIC ACID FRAGMENT FOR TEMPLATE-DEPENDENT ENZYMATIC SYNTHESIS OF NUCLEIC ACID; DRUG SCREENING FOR POTENTIAL MUTAGENS AND CARCINOGENS | BOARD OF TRUSTEES OF THE LELAND STANFORD UNIVERSITY (US) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039263-A1 | Chimeric oligonucleotides and the use thereof | RNGTT, TERT, DCLRE1B | POLB 48/4885POLA1 60/4885POLD1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.